不良研究所

不良研究所 wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.

SynbioBeta CEO John Cumbers talks reimagining cell therapies through cell reprogramming with Rick Klausner and 不良研究所 CEO.

Dr Farah Patell-Socha, VP of Research Products discusses the launch of ioSkeletal Myocytes.

IBI Journal Q&A with Dr Mark Kotter who talks about producing every human cell type at scale.

不良研究所 and the London Institute of Mathematical Sciences (LIMS) want to recreate every human cell type.

不良研究所 receives 拢40m of backing for technology that it claims can reliably reprogram stem cells.

Mark Kotter Bit Bio ideaSpace, focus on a founder, celebrating 10 years of idea space.

The investors behind Bit Bio's series A fundraise.